1. Fundamental Financial Data
Eli Lilly's
Free Cash Flow
|
||||||||||
USD Mil
|
2005
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013
|
2014
|
Operating
Cash Flow
|
1914
|
3976
|
5155
|
7296
|
4336
|
6857
|
7235
|
5305
|
5735
|
4367
|
Cap Spending
|
-1298
|
-1078
|
-1082
|
-947
|
-855
|
-1187
|
-1693
|
-1044
|
-1093
|
-1471
|
Free Cash
Flow
|
616
|
2898
|
4072
|
6348
|
3481
|
5670
|
5542
|
4261
|
4642
|
2896
|
Free Cash
Flow/Sales
|
4.2
|
18.47
|
21.85
|
31.15
|
15.94
|
24.57
|
22.82
|
18.85
|
20.08
|
14.76
|
Eli Lilly's
Profitability Numbers
|
||||||||||
2005
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013
|
2014
|
|
Operating
Margin
|
24.91
|
26.29
|
21.77
|
3.4
|
25.59
|
28.3
|
22.76
|
23.93
|
23.24
|
16.97
|
Net Margin
|
13.52
|
16.97
|
15.85
|
-10.17
|
19.82
|
21.97
|
17.9
|
18.09
|
20.27
|
12.19
|
Asset
Turnover
|
0.59
|
0.67
|
0.76
|
0.73
|
0.77
|
0.79
|
0.75
|
0.66
|
0.66
|
0.54
|
Return on
Assets
|
8.01
|
11.44
|
12.12
|
-7.4
|
15.28
|
17.34
|
13.45
|
12.01
|
13.45
|
6.6
|
Financial Leverage
|
2.28
|
2
|
1.96
|
4.34
|
2.88
|
2.5
|
2.49
|
2.33
|
2
|
2.42
|
Return on
Equity
|
18.24
|
24.46
|
23.96
|
-20.31
|
53.25
|
46.2
|
33.49
|
28.89
|
28.92
|
14.49
|
Eli Lilly's
Revenue Growth
|
||||||||||
2005
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013
|
2014
|
|
Year over Year
|
5.68
|
7.14
|
18.75
|
9.36
|
7.15
|
5.68
|
5.25
|
-6.93
|
2.26
|
-15.13
|
3-Year
Average
|
9.75
|
7.64
|
10.37
|
11.64
|
11.65
|
7.39
|
6.02
|
1.16
|
0.05
|
-6.87
|
10-Year
Average
|
8.03
|
7.88
|
8.14
|
8.23
|
8.12
|
7.83
|
7.72
|
7.39
|
6.27
|
3.54
|
Facing a very steep patent cliff in 2014, Eli
Lilly got a pretty low ROA and ROE comparing previous year. In addition, Eli Lilly confronted lowest YOY revenue growth rate. However,
the good news is Eli Lilly had a stable positive free cash flow in past ten
years.
2. Segment
Sales
Eli
Lilly’s largest portion of revenue is from Endocrinology drugs followed by
Neuroscience drugs and Oncology drugs. Animal health segment had a better
profit margin comparing to human pharmaceutical products.
3. Industry
Overview
Eli Lilly’s gross profit is higher than
industry average. However, its profit margin didn’t higher than industry
average. The reason is that Eli Lilly tends to spend over 20% of its sales on R&D,
much higher than the industry average. Before 2014, Eli Lilly’s ROA and ROE are
higher than industry average. However, it’s ROA and ROE in 2014 are much lower
than industry average.
Reference: Data from Morningstar.com and Eli Lilly's annual report
Reference: Data from Morningstar.com and Eli Lilly's annual report
0 意見:
張貼留言